Literature DB >> 24308779

Semiparametric Bayesian commensurate survival model for post-market medical device surveillance with non-exchangeable historical data.

Thomas A Murray1, Brian P Hobbs, Theodore C Lystig, Bradley P Carlin.   

Abstract

Trial investigators often have a primary interest in the estimation of the survival curve in a population for which there exists acceptable historical information from which to borrow strength. However, borrowing strength from a historical trial that is non-exchangeable with the current trial can result in biased conclusions. In this article we propose a fully Bayesian semiparametric method for the purpose of attenuating bias and increasing efficiency when jointly modeling time-to-event data from two possibly non-exchangeable sources of information. We illustrate the mechanics of our methods by applying them to a pair of post-market surveillance datasets regarding adverse events in persons on dialysis that had either a bare metal or drug-eluting stent implanted during a cardiac revascularization surgery. We finish with a discussion of the advantages and limitations of this approach to evidence synthesis, as well as directions for future work in this area. The article's Supplementary Materials offer simulations to show our procedure's bias, mean squared error, and coverage probability properties in a variety of settings.
© 2013, The International Biometric Society.

Entities:  

Keywords:  Bayesian hierarchical modeling; Commensurate prior; Evidence synthesis; Flexible proportional hazards model; Hazard smoothing; Non-exchangeable sources of data

Mesh:

Year:  2013        PMID: 24308779      PMCID: PMC3954409          DOI: 10.1111/biom.12115

Source DB:  PubMed          Journal:  Biometrics        ISSN: 0006-341X            Impact factor:   2.571


  7 in total

1.  The BUGS project: Evolution, critique and future directions.

Authors:  David Lunn; David Spiegelhalter; Andrew Thomas; Nicky Best
Journal:  Stat Med       Date:  2009-11-10       Impact factor: 2.373

2.  About an adaptively weighted Kaplan-Meier estimate.

Authors:  Jean-François Plante
Journal:  Lifetime Data Anal       Date:  2009-06-17       Impact factor: 1.588

Review 3.  The combination of randomized and historical controls in clinical trials.

Authors:  S J Pocock
Journal:  J Chronic Dis       Date:  1976-03

4.  Hierarchical commensurate and power prior models for adaptive incorporation of historical information in clinical trials.

Authors:  Brian P Hobbs; Bradley P Carlin; Sumithra J Mandrekar; Daniel J Sargent
Journal:  Biometrics       Date:  2011-03-01       Impact factor: 2.571

5.  Commensurate Priors for Incorporating Historical Information in Clinical Trials Using General and Generalized Linear Models.

Authors:  Brian P Hobbs; Daniel J Sargent; Bradley P Carlin
Journal:  Bayesian Anal       Date:  2012-08-28       Impact factor: 3.728

6.  Adaptive adjustment of the randomization ratio using historical control data.

Authors:  Brian P Hobbs; Bradley P Carlin; Daniel J Sargent
Journal:  Clin Trials       Date:  2013       Impact factor: 2.486

7.  Long-term survival and repeat coronary revascularization in dialysis patients after surgical and percutaneous coronary revascularization with drug-eluting and bare metal stents in the United States.

Authors:  Gautam R Shroff; Craig A Solid; Charles A Herzog
Journal:  Circulation       Date:  2013-04-09       Impact factor: 29.690

  7 in total
  9 in total

1.  Detecting and accounting for violations of the constancy assumption in non-inferiority clinical trials.

Authors:  Joseph S Koopmeiners; Brian P Hobbs
Journal:  Stat Methods Med Res       Date:  2016-09-01       Impact factor: 3.021

2.  Bayesian hierarchical modeling based on multisource exchangeability.

Authors:  Alexander M Kaizer; Joseph S Koopmeiners; Brian P Hobbs
Journal:  Biostatistics       Date:  2018-04-01       Impact factor: 5.899

3.  Bayesian hierarchical methods for meta-analysis combining randomized-controlled and single-arm studies.

Authors:  Jing Zhang; Chia-Wen Ko; Lei Nie; Yong Chen; Ram Tiwari
Journal:  Stat Methods Med Res       Date:  2018-02-13       Impact factor: 3.021

4.  Borrowing from Historical Control Data in Cancer Drug Development: A Cautionary Tale and Practical Guidelines.

Authors:  Connor Jo Lewis; Somnath Sarkar; Jiawen Zhu; Bradley P Carlin
Journal:  Stat Biopharm Res       Date:  2019-04-22       Impact factor: 1.452

5.  COMBINING NONEXCHANGEABLE FUNCTIONAL OR SURVIVAL DATA SOURCES IN ONCOLOGY USING GENERALIZED MIXTURE COMMENSURATE PRIORS.

Authors:  Thomas A Murray; Brian P Hobbs; Bradley P Carlin
Journal:  Ann Appl Stat       Date:  2015-11-02       Impact factor: 2.083

6.  Dynamic borrowing in the presence of treatment effect heterogeneity.

Authors:  Ales Kotalik; David M Vock; Eric C Donny; Dorothy K Hatsukami; Joseph S Koopmeiners
Journal:  Biostatistics       Date:  2021-10-13       Impact factor: 5.899

Review 7.  A Framework for Methodological Choice and Evidence Assessment for Studies Using External Comparators from Real-World Data.

Authors:  Christen M Gray; Fiona Grimson; Deborah Layton; Stuart Pocock; Joseph Kim
Journal:  Drug Saf       Date:  2020-07       Impact factor: 5.606

8.  Including historical data in the analysis of clinical trials: Is it worth the effort?

Authors:  Joost van Rosmalen; David Dejardin; Yvette van Norden; Bob Löwenberg; Emmanuel Lesaffre
Journal:  Stat Methods Med Res       Date:  2017-02-21       Impact factor: 3.021

9.  Bayesian survival analysis for early detection of treatment effects in phase 3 clinical trials.

Authors:  Lucie Biard; Anne Bergeron; Vincent Lévy; Sylvie Chevret
Journal:  Contemp Clin Trials Commun       Date:  2021-01-09
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.